An interventional study of Behavioral Activation Therapy App and Telehealth Delivered Behavioral Activation in Depression, sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Depression by Medical University of South Carolina — 17 open to participants now, 21 under way, none of them phase 3. Depression · Medical University of South Carolina.
Among the 47 studies in Depression by Medical University of South Carolina, this one is the 25th largest by planned enrollment of the 45 interventional ones that give a count, is one of 6 that started in 2026, is one of 31 with no phase, reaches primary completion later than 8 of the 20 other live ones, and was the 45th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →17 of the 47 studies in Depression by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 18–70
Medical University of South Carolina · Sites in United States
Ages 18–80
Medical University of South Carolina · Sites in United States
Ages 18+
Medical University of South Carolina · Sites in United States
Ages 18+
Medical University of South Carolina · Sites in United States
Ages 40+
By country, each count listing its studies:
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 10 · Phase 3 5 · Phase 4 3
First in 2005; this study’s year is marked. 6 started in 2026.
This study's planned enrollment of 40 is below the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 46 across the 45 interventional studies, 10 across the 2 observational. Of the 24 that completed or were terminated, 14 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
Medical University of South Carolina is the lead sponsor of 875 studies on the registry; 165 are open to participants now.
Of its 132 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.
10 of the studies in Depression by Medical University of South Carolina that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657432Medical University of South CarolinaBrief, High-dose rTMS for Depression | 2026-12-01 |
| NCT07226011Medical University of South CarolinaAccelerated High-Dose tDCS for Depression | 2026-12-28 |
| NCT07369557Medical University of South CarolinaMindfulness Training During Accelerated TMS for Depression | 2026-12-30 |
| NCT06748209Medical University of South CarolinaEstablishing Mobile Transcranial Magnetic Stimulation | 2027-03-01 |
| NCT05497115Medical University of South CarolinaTesting a Scalable Model of Care to Improve Patients Access to Mental Health Services After Traumatic Injury | 2027-03-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 47 studies in Depression by Medical University of South Carolina, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This pilot, three-arm randomized clinical trial (N=40; 2:1:1) will evaluate the feasibility and preliminary efficacy of a digitally enhanced stepped-care approach for depression treatment in primary care. Participants will be randomized to: (1) stepped-care beginning with a self-guided Behavioral Activation app (Moodivate), with stepping to clinician-delivered telebehavioral health Behavioral Activation at Week 2 based on app engagement and early PHQ-9 change; (2) telebehavioral health Behavioral Activation; or (3) Moodivate alone. The primary endpoint is feasibility of the stepped-care approach, defined as continued engagement after stepping (≥1 Moodivate use/week for >4 weeks or ≥4 therapy sessions). The secondary endpoint is change in PHQ-9 scores from baseline through Week 12. The study will be conducted within MUSC Primary Care clinics across South Carolina using remote screening, e-consent, and REDCap assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants randomized to the Digitally-Enhanced Stepped Care condition will be instructed to utilize a Behavioral Activation therapy focused mobile application called "Moodivate" regularly, at least once per day, for the treatment of depressed mood among cancer survivors. Participants in the Digitally-Enhanced Stepped Care group will receive a download code to download the Moodivate mobile application. Moodivate is a mobile app for individuals with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, and rate mood daily. Participants will be asked to complete questionnaire measures at baseline and weeks 1, 2, 4, 6, 8, and 12. App engagement will be passively monitored for two weeks following initial download to determine whether care needs to be stepped up to guideline-concordant standard care.
Behavioral: Behavioral Activation Therapy App
Participants randomized to the Moodivate condition will be instructed to utilize Moodivate regularly, at least once per day, for the treatment of depressed mood. Participants in the Moodivate group will receive a download code to download the Moodivate mobile application. Moodivate is a mobile app for individuals with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, and rate mood daily. Participants will be asked to complete questionnaire measures at baseline and weeks 1, 2, 4, 6, 8, and 12.
Behavioral: Behavioral Activation Therapy App
Participants randomized to the Telebehavioral Health condition will receive 8 sessions of telehealth-delivered Behavioral Activation therapy with a mental health provider over a 10 week period. Participants will be asked to complete questionnaire measures at baseline and weeks 1, 2, 4, 6, 8, and 10.
Behavioral: Telehealth Delivered Behavioral Activation
Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures at baseline and weeks 1, 2, 4, 6, 8, and 12.
8 sessions of telehealth-delivered Behavioral Activation with a mental health provider over a 10-week period.
Feasibility of Digitally Enhanced Stepped-Care
We operationalize feasibility as continued engagement after stepping, defined as either using Moodivate at least once per week for \>4 weeks (for engagers) or attending \>4 telebehavioral health sessions (for non-engagers). We selected 4 treatment sessions as meaningful engagement because all BA concepts are introduced to patients within sessions 1-4, and sessions 5-8 primarily reinforce previous concepts. Because a strength of self-guided DMHIs is highly flexible pacing, we opt to base meaningful DMHI engagement on continued app use over time, for a duration of \>4 weeks to be comparable to the BA feasibility benchmark. Digitally enhanced stepped-care will be considered feasible if \>75% of participants meet these feasibility benchmarks.
Time frame: 12 weeks
Change Over Time in Depression Severity
Depression will be assessed via the PHQ-9 at baseline and all follow-ups. The PHQ-9 has high sensitivity and specificity for identifying depression.
Time frame: 12 weeks
Started Jul 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 11 months is below that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of South Carolina →